A Phase II, multicentric, randomized, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily to patients with diarrhea-predominant irritable bowel syndrome (IBS-D) | Publicación